BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 25106088)

  • 1. Acquired and intrinsic resistance in cancer immunotherapy.
    Kelderman S; Schumacher TN; Haanen JB
    Mol Oncol; 2014 Sep; 8(6):1132-9. PubMed ID: 25106088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunoediting and resistance to T cell-based immunotherapy.
    O'Donnell JS; Teng MWL; Smyth MJ
    Nat Rev Clin Oncol; 2019 Mar; 16(3):151-167. PubMed ID: 30523282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.
    Trujillo JA; Sweis RF; Bao R; Luke JJ
    Cancer Immunol Res; 2018 Sep; 6(9):990-1000. PubMed ID: 30181337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Pennock GK; Chow LQ
    Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapies and Combination Strategies for Immuno-Oncology.
    Barbari C; Fontaine T; Parajuli P; Lamichhane N; Jakubski S; Lamichhane P; Deshmukh RR
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cancer immunotherapy by immuno-checkpoint blockade].
    Kawakami Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.
    Bonavida B; Chouaib S
    Ann Oncol; 2017 Mar; 28(3):457-467. PubMed ID: 27864216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
    Saleh R; Elkord E
    Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).
    Ascierto PA; Bifulco C; Buonaguro L; Emens LA; Ferris RL; Fox BA; Delgoffe GM; Galon J; Gridelli C; Merlano M; Nathan P; Odunsi K; Okada H; Paulos CM; Pignata S; Schalper KA; Spranger S; Tortora G; Zarour H; Butterfield LH; Puzanov I
    J Immunother Cancer; 2019 Nov; 7(1):332. PubMed ID: 31783779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities.
    Bashash D; Zandi Z; Kashani B; Pourbagheri-Sigaroodi A; Salari S; Ghaffari SH
    J Cell Physiol; 2022 Jan; 237(1):346-372. PubMed ID: 34498289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
    Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
    Front Immunol; 2021; 12():777073. PubMed ID: 34868044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.
    Leko V; Rosenberg SA
    Cancer Cell; 2020 Oct; 38(4):454-472. PubMed ID: 32822573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.
    Kishton RJ; Sukumar M; Restifo NP
    Cell Metab; 2017 Jul; 26(1):94-109. PubMed ID: 28683298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer.
    Bellone M; Elia AR
    Cytokine Growth Factor Rev; 2017 Aug; 36():17-24. PubMed ID: 28606732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-resistant mechanisms in cancer immunotherapy.
    Kawakami Y; Ohta S; Sayem MA; Tsukamoto N; Yaguchi T
    Int J Clin Oncol; 2020 May; 25(5):810-817. PubMed ID: 31919690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
    Fares CM; Van Allen EM; Drake CG; Allison JP; Hu-Lieskovan S
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():147-164. PubMed ID: 31099674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
    Gajewski TF
    Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis: a
    Lee YG; Yang N; Chun I; Porazzi P; Carturan A; Paruzzo L; Sauter CT; Guruprasad P; Pajarillo R; Ruella M
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37055217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.